Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer

NCT ID: NCT00145418

Last Updated: 2014-06-30

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-02-28
• Study Completion Date: 2010-03-31

Brief Summary

It has been accepted and proven that patients with unresectable lung cancer can benefit from systemic chemotherapy. Traditional platinum-based therapy has significant side effects. Oxaliplatin and docetaxel have both shown to be effective for lung cancer. The purpose of this study is to determine if oxaliplatin combined with docetaxel has a lower toxicity profile and to determine the response rate to this study drug combination.

Detailed Description

This study is a Phase II study designed to evaluate the toxicity profile for oxaliplatin and docetaxel and to determine the response rate to this study drug combination. The primary objective of the study is response rate by RECIST criteria. The secondary objective is time to progression, duration of response, and toxicity. Patients will receive:

• oxaliplatin 85mg/m2 over 2 hours on Days 1 and 15
• docetaxel 30mg/m2 on Days 1 and 8

Cycles are to be repeated every 28 days for a maximum of 6 cycles.

Conditions

Carcinoma, Non-Small-Cell Lung

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Oxaliplatin + Docetaxel as first line therapy of Stage IV or IIIB unresectable non-small cell lung cancer. The primary objective of the trial is to determine the response rate by RECIST criteria to the combination of oxaliplatin and docetaxel in patients with previously untreated NSCLC.

Group Type: EXPERIMENTAL

Oxaliplatin + Docetaxel

Intervention Type: DRUG

Oxaliplatin 85mg/m2 Docetaxel 30mg.m2

Interventions

Oxaliplatin + Docetaxel

Oxaliplatin 85mg/m2 Docetaxel 30mg.m2

Intervention Type: DRUG

Other Intervention Names

Eloxatin

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC)
• Patients must have measurable disease
• Age greater than or equal to 18 years
• ECOG performance score of 0, 1, or 2
• Absolute neutrophil count (ANC) > 1,500
• Platelets > 100,000
• Serum creatinine < 1.5mg/dL
• Serum total bilirubin < 1.5mg/dL
• Alkaline phosphatase < 3 times the upper limit of normal
• SGOT/SGPT < 3 times the upper limit of normal
• Patients must be recovered from the effects of any prior surgery or RT.
• Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial.
• Patients of childbearing potential and their partners must agree to use an effective form of contraception during the study and for 90 days following the last dose of study medications.

Exclusion Criteria

• Patients with an active infection > 38.5 degrees Celsius within 3 days of the first scheduled day of protocol treatment
• Patients with active central nervous system (CNS) metastasis. Patients with stable CNS disease, who have undergone radiotherapy at least 4 weeks prior to the planned first protocol treatment and who have been on a stable dose of corticosteroids for 2 weeks are eligible for the trial.
• History of prior malignancy within the past 5 years except for curatively treated basal cell carcinoma of the skin; cervical intra-epithelial neoplasm, or localized prostate cancer with a current prostate specific antigen (PSA) of < 1.0 mg/dL
• Patients with known hypersensitivity to any of the components of oxaliplatin or docetaxel
• Patients who have had prior chemotherapy for lung cancer
• Patients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of the first scheduled day of protocol treatment
• Grade 2 peripheral neuropathy
• Patients who are pregnant or lactating
• Any other medical condition, including mental illness or substance abuse deemed by the investigator to be likely to interfere with the patients' ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results
• History of allogeneic transplant
• Known HIV, hepatitis B or C (active, previously treated, or both)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi-Synthelabo

INDUSTRY

Sponsor Role: collaborator

Oncology Specialists, S.C.

OTHER

Sponsor Role: lead

Responsible Party

Dr. Sigrun Hallmeyer

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Chadi Nabhan, MD

Role: PRINCIPAL_INVESTIGATOR

Oncology Specialists, SC

Locations

Oncology Specialists, SC

Park Ridge, Illinois, United States

Countries

United States

Other Identifiers

OX-03-137 (0409)

Identifier Type: -

Identifier Source: org_study_id

NCT00393081

Identifier Type: -

Identifier Source: nct_alias